|
1
|
Zhang D and Fan D: New insights into the
mechanisms of gastric cancer multidrug resistance and future
perspectives. Future Oncol. 6:527–537. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Du X, Liu B, Luan X, Cui Q and Li L:
miR-30 decreases multidrug resistance in human gastric cancer cells
by modulating cell autophagy. Exp Ther Med. 15:599–605.
2018.PubMed/NCBI
|
|
3
|
Ozben T: Mechanisms and strategies to
overcome multiple drug resistance in cancer. FEBS Lett.
580:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma Y, Wei X and Wu Z: HNF-4α promotes
multidrug resistance of gastric cancer cells through the modulation
of cell apoptosis. Oncol Lett. 14:6477–6484. 2017.
|
|
5
|
Colotti G, Poser E, Fiorillo A, Genovese
I, Chiarini V and Ilari A: Sorcin, a calcium binding protein
involved in the multidrug resistance mechanisms in cancer cells.
Molecules. 19:13976–13989. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ilari A, Johnson KA, Nastopoulos V,
Verzili D, Zamparelli C, Colotti G, Tsernoglou D and Chiancone E:
The crystal structure of the sorcin calcium binding domain provides
a model of Ca2+-dependent processes in the full-length
protein. J Mol Biol. 317:447–458. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Genovese I, Fiorillo A, Ilari A,
Masciarelli S, Fazi F and Colotti G: Binding of doxorubicin to
Sorcin impairs cell death and increases drug resistance in cancer
cells. Cell Death Dis. 8:e29502017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deng L, Su T, Leng A, Zhang X, Xu M, Yan
L, Gu H and Zhang G: Upregulation of soluble resistance-related
calcium-binding protein (sorcin) in gastric cancer. Med Oncol.
27:1102–1108. 2010. View Article : Google Scholar
|
|
9
|
Yamagishi N, Nakao R, Kondo R, Nishitsuji
M, Saito Y, Kuga T, Hatayama T and Nakayama Y: Increased expression
of sorcin is associated with multidrug resistance in leukemia cells
via up-regulation of MDR1 expression through cAMP response
element-binding protein. Biochem Biophys Res Commun. 448:430–436.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Van der Bliek AM, Meyers MB, Biedler JL,
Hes E and Borst P: A 22-kd protein (sorcin/V19) encoded by an
amplified gene in multidrug-resistant cells, is homologous to the
calcium-binding light chain of calpain. EMBO J. 5:3201–3208. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He Q, Zhang G, Hou D, Leng A, Xu M, Peng J
and Liu T: Overexpression of sorcin results in multidrug resistance
in gastric cancer cells with up-regulation of P-gp. Oncol Rep.
25:237–243. 2011.
|
|
12
|
Gong Z, Sun P, Chu H, Zhu H, Sun D and
Chen J: Overexpression of sorcin in multidrug-resistant human
breast cancer. Oncol Lett. 8:2393–2398. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yi H, Yang YX, Tang CE, Chen ZC, Zhang GY
and Xiao ZQ: Sorcin overexpression and multidrug resistance in
human gastric cancer cells. Zhong Nan Da Xue Xue Bao Yi Xue Ban.
31:340–344. 3492006.In Chinese.
|
|
14
|
Xu P, Jiang YF and Wang JH: shRNA-mediated
silencing of sorcin increases drug chemosensitivity in myeloma
KM3/DDP and U266/ADM cell lines. Int J Clin Exp Pathol.
8:2300–2310. 2015.PubMed/NCBI
|
|
15
|
Hu Y, Li S, Yang M, Yan C, Fan D, Zhou Y,
Zhang Y, Yagüe E and Xiong D: Sorcin silencing inhibits
epithelial-to-mesenchymal transition and suppresses breast cancer
metastasis in vivo. Breast Cancer Res Treat. 143:287–299. 2014.
View Article : Google Scholar
|
|
16
|
Macfarlane LA and Murphy PR: MicroRNA:
Biogenesis, function and role in cancer. Curr Genomics. 11:537–561.
2010. View Article : Google Scholar
|
|
17
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han C, Yu Z, Duan Z and Kan Q: Role of
microRNA-1 in human cancer and its therapeutic potentials. BioMed
Res Int. 2014:4283712014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie M, Dart DA, Guo T, Xing XF, Cheng XJ,
Du H, Jiang WG, Wen XZ and Ji JF: MicroRNA-1 acts as a tumor
suppressor microRNA by inhibiting angiogenesis-related growth
factors in human gastric cancer. Gastric Cancer. 21:41–54. 2018.
View Article : Google Scholar :
|
|
20
|
Li J, Guan J, Long X, Wang Y and Xiang X:
mir-1-mediated paracrine effect of cancer-associated fibroblasts on
lung cancer cell proliferation and chemoresistance. Oncol Rep.
35:3523–3531. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu M, Zheng S, Zhang X, Guo H, Shi X,
Kang X, Qu Y, Hu Z and Tian J: Cerenkov luminescence imaging on
evaluation of early response to chemotherapy of drug-resistant
gastric cancer. Nanomedicine. 14:205–213. 2018. View Article : Google Scholar
|
|
22
|
Wang Y, Wu K, Yang Z, Zhao Q and Fan D, Xu
P, Nie Y and Fan D: Multidrug-resistance related long non-coding
RNA expression profile analysis of gastric cancer. PLoS One.
10:e01354612015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu YC, Liu X, Li M, Li Y, Li CY, Lu Y,
Sanches J, Wang L, Du Y, Mao LM, et al: A novel mechanism of
doxorubicin resistance and tumorigenesis mediated by
microRNA-501-5p-suppressed BLID. Mol Ther Nucleic Acids.
12:578–590. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koontz MZ, Horning SJ, Balise R, Greenberg
PL, Rosenberg SA, Hoppe RT and Advani RH: Risk of therapy-related
secondary leukemia in Hodgkin lymphoma: The Stanford University
experience over three generations of clinical trials. J Clin Oncol.
31:592–598. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Waqar SN and Morgensztern D: Treatment
advances in small cell lung cancer (SCLC). Pharmacol Ther.
180:16–23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dower CM, Bhat N, Gebru MT, Chen L, Wills
CA, Miller BA and Wang HG: Targeted inhibition of ULK1 promotes
apoptosis and suppresses tumor growth and metastasis in
neuroblastoma. Mol Cancer Ther. 17:2365–2376. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
28
|
Chen QN, Wei CC, Wang ZX and Sun M: Long
non-coding RNAs in anti-cancer drug resistance. Oncotarget.
8:1925–1936. 2017.
|
|
29
|
Sui H, Cai GX, Pan SF, Deng WL, Wang YW,
Chen ZS, Cai SJ, Zhu HR and Li Q: miR200c attenuates P-gp-mediated
MDR and metastasis by targeting JNK2/c-Jun signaling pathway in
colorectal cancer. Mol Cancer Ther. 13:3137–3151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xie M, Dart DA, Owen S, Wen X, Ji J and
Jiang W: Insights into roles of the miR-1, -133 and -206 family in
gastric cancer (Review). Oncol Rep. 36:1191–1198. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cao W, Wei W, Zhan Z, Xie D, Xie Y and
Xiao Q: Regulation of drug resistance and metastasis of gastric
cancer cells via the microRNA647-ANK2 axis. Int J Mol Med.
41:1958–1966. 2018.PubMed/NCBI
|
|
32
|
Yan Z, Xiong Y, Xu W, Gao J, Cheng Y, Wang
Z, Chen F and Zheng G: Identification of hsa-miR-335 as a
prognostic signature in gastric cancer. PLoS One. 7:e400372012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mataki H, Enokida H, Chiyomaru T, Mizuno
K, Matsushita R, Goto Y, Nishikawa R, Higashimoto I, Samukawa T,
Nakagawa M, et al: Downregulation of the microRNA-1/133a cluster
enhances cancer cell migration and invasion in lung-squamous cell
carcinoma via regulation of Coronin1C. J Hum Genet. 60:53–61. 2015.
View Article : Google Scholar
|
|
34
|
Chang YS, Chen WY, Yin JJ,
Sheppard-Tillman H, Huang J and Liu YN: EGF receptor promotes
prostate cancer bone metastasis by downregulating miR-1 and
activating TWIST1. Cancer Res. 75:3077–3086. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu L, Zhang Y, Wang H, Zhang G, Ding Y and
Zhao L: Tumor suppressor miR-1 restrains epithelial-mesenchymal
transition and metastasis of colorectal carcinoma via the MAPK and
PI3K/AKT pathway. J Transl Med. 12:2442014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsai KW, Hu LY, Chen TW, Li SC, Ho MR, Yu
SY, Tu YT, Chen WS and Lam HC: Emerging role of microRNAs in
modulating endothelin-1 expression in gastric cancer. Oncol Rep.
33:485–493. 2015. View Article : Google Scholar
|
|
37
|
Nasser MW, Datta J, Nuovo G, Kutay H,
Motiwala T, Majumder S, Wang B, Suster S, Jacob ST and Ghoshal K:
Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression
of tumorigenic property of lung cancer cells and their
sensitization to doxorubicin-induced apoptosis by miR-1. J Biol
Chem. 283:33394–33405. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Beale PJ, Rogers P, Boxall F, Sharp SY and
Kelland LR: BCL-2 family protein expression and platinum drug
resistance in ovarian carcinoma. Br J Cancer. 82:436–440. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen J, Wang L, Tang Y, Gong G, Liu L,
Chen M, Chen Z, Cui Y, Li C, Cheng X, et al: Maspin enhances
cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and
correlates with prognosis of muscle-invasive bladder cancer
patients receiving cisplatin based neoadjuvant chemotherapy. J Exp
Clin Cancer Res. 35:22016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hu Y, Cheng X, Li S, Zhou Y, Wang J, Cheng
T, Yang M and Xiong D: Inhibition of sorcin reverses multidrug
resistance of K562/A02 cells and MCF-7/A02 cells via regulating
apoptosis-related proteins. Cancer Chemother Pharmacol. 72:789–798.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tainton KM, Smyth MJ, Jackson JT, Tanner
JE, Cerruti L, Jane SM, Darcy PK and Johnstone RW: Mutational
analysis of P-glycoprotein: Suppression of caspase activation in
the absence of ATP-dependent drug efflux. Cell Death Differ.
11:1028–1037. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
de Groot DJ, van der Deen M, Le TK,
Regeling A, de Jong S and de Vries EG: Indomethacin induces
apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant
small-cell lung cancer cells overexpressing MRP1. Br J Cancer.
97:1077–1083. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ye CG, Wu WK, Yeung JH, Li HT, Li ZJ, Wong
CC, Ren SX, Zhang L, Fung KP and Cho CH: Indomethacin and SC236
enhance the cytotoxicity of doxorubicin in human hepatocellular
carcinoma cells via inhibiting P-glycoprotein and MRP1 expression.
Cancer Lett. 304:90–96. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang YH, Imai Y, Shiseki M, Tanaka J and
Motoji T: Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces
MDR1/P-glycoprotein expression in multidrug resistant leukemic
cells and inhibits leukemic cell proliferation. Leuk Res.
67:99–108. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tuo H, Shu F, She S, Yang M, Zou XQ, Huang
J, Hu HD, Hu P, Ren H, Peng SF, et al: Sorcin induces gastric
cancer cell migration and invasion contributing to STAT3
activation. Oncotarget. 8:104258–104271. 2017. View Article : Google Scholar : PubMed/NCBI
|
